130 related articles for article (PubMed ID: 20646334)
1. Efforts to counteract locally the effects of systemic immunosupression: a review on the use of imiquimod, a topical immunostimulator in organ transplant recipients.
Trakatelli M; Katsanos G; Ulrich C; Kalabalikis D; Sotiriadis D; Stockfleth E
Int J Immunopathol Pharmacol; 2010; 23(2):387-96. PubMed ID: 20646334
[TBL] [Abstract][Full Text] [Related]
2. Viral warts in organ transplant recipients: new aspects in therapy.
Schmook T; Nindl I; Ulrich C; Meyer T; Sterry W; Stockfleth E
Br J Dermatol; 2003 Nov; 149 Suppl 66():20-4. PubMed ID: 14616341
[TBL] [Abstract][Full Text] [Related]
3. 5% topical imiquimod tolerance in transplant recipients.
Ben M'barek L; Mebazaa A; Euvrard S; Frances C; Thervet E; Morel P; Menasché S; Legendre C; Lebbe C
Dermatology; 2007; 215(2):130-3. PubMed ID: 17684375
[TBL] [Abstract][Full Text] [Related]
4. [New perspective in immunotherapy: local imiquimod treatment].
Kemény L; Nagy N
Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
[TBL] [Abstract][Full Text] [Related]
5. Imiquimod in dermatology: an overview.
Hanna E; Abadi R; Abbas O
Int J Dermatol; 2016 Aug; 55(8):831-44. PubMed ID: 27387373
[TBL] [Abstract][Full Text] [Related]
6. Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.
Quist SR; Gollnick HP
Expert Opin Pharmacother; 2011 Feb; 12(3):451-61. PubMed ID: 21254950
[TBL] [Abstract][Full Text] [Related]
7. Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients.
Célestin Schartz NE; Chevret S; Paz C; Kerob D; Verola O; Morel P; Lebbé C
J Am Acad Dermatol; 2008 Apr; 58(4):585-91. PubMed ID: 18068265
[TBL] [Abstract][Full Text] [Related]
8. [Photodynamic therapy vs imiquimod].
Serra-Guillén C; Nagore E; Guillén C
Actas Dermosifiliogr; 2012; 103(6):488-501. PubMed ID: 22178262
[TBL] [Abstract][Full Text] [Related]
9. Use of topical immunomodulators in organ transplant recipients.
Kovach BT; Stasko T
Dermatol Ther; 2005; 18(1):19-27. PubMed ID: 15842609
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Imiquimod 3.75% from Lmax in Actinic Keratosis According to Fitzpatrick Skin Type.
Alomar A; Stockfleth E; Dirschka T; Gupta G; Aractingi S; Dakovic R; Peris K
J Drugs Dermatol; 2016 Mar; 15(3):285-9. PubMed ID: 26954313
[TBL] [Abstract][Full Text] [Related]
11. Imiquimod 5% cream for the treatment of actinic keratoses.
Somani N; Rivers JK
Skin Therapy Lett; 2005 Mar; 10(2):1-6. PubMed ID: 15986078
[TBL] [Abstract][Full Text] [Related]
12. Development of recalcitrant skin ulcers as a side-effect of treatment with topical 5% imiquimod cream: report of two cases.
Kalampalikis A; Goetze S; Elsner P
J Eur Acad Dermatol Venereol; 2014 Nov; 28(11):1574-6. PubMed ID: 24456017
[No Abstract] [Full Text] [Related]
13. Imiquimod induces sustained remission of actinic damage: a case report spanning one decade of observation.
Knackstedt TJ; Quitadamo M
Cutis; 2015 Feb; 95(2):E20-3. PubMed ID: 25750973
[TBL] [Abstract][Full Text] [Related]
14. The use of imiquimod in the treatment of periocular tumours.
Ross AH; Kennedy CT; Collins C; Harrad RA
Orbit; 2010 Apr; 29(2):83-7. PubMed ID: 20394545
[TBL] [Abstract][Full Text] [Related]
15. Imiquimod 5% cream for actinic keratosis.
Perras C
Issues Emerg Health Technol; 2004 Sep; (61):1-4. PubMed ID: 15382379
[TBL] [Abstract][Full Text] [Related]
16. A case of imiquimod-induced alopecia.
Conde J; Davis K; Ntuen E; Balmer N; Jones D; McMichael A
J Dermatolog Treat; 2010 Mar; 21(2):122-4. PubMed ID: 19488918
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial.
Brown VL; Atkins CL; Ghali L; Cerio R; Harwood CA; Proby CM
Arch Dermatol; 2005 Aug; 141(8):985-93. PubMed ID: 16103328
[TBL] [Abstract][Full Text] [Related]
18. Imiquimod-induced hypopigmentation following treatment of periungual verruca vulgaris.
Edgar N; Pilkington S; Hogan DJ
Cutis; 2018 Jun; 101(6):466-468. PubMed ID: 30063776
[TBL] [Abstract][Full Text] [Related]
19. Beyond a decade of 5% imiquimod topical therapy.
A Gaspari A; Tyring SK; Rosen T
J Drugs Dermatol; 2009 May; 8(5):467-74. PubMed ID: 19537370
[TBL] [Abstract][Full Text] [Related]
20. Increased number of mast cells in the dermis in actinic keratosis lesions effectively treated with imiquimod.
Oyama S; Funasaka Y; Tsuchiya SI; Kawana S; Saeki H
J Dermatol; 2017 Aug; 44(8):944-949. PubMed ID: 28342266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
